Island Pharmaceuticals Ltd has released a press release.
Island receives ethics approval for ISLA-101 study
Filed with ASX ·
6ix hasn’t read this filing yet.
Island Pharmaceuticals Ltd on 6ix
In the deck
Story so far
Earlier from Island Pharmaceuticals
- ILA granted key Australian patent for ISLA-101
- Quarterly Activity Report & Appendix 4C
- ISLA-101 Single Ascending Dose study update
- Island Pharmaceuticals granted key U.S. patent for ISLA-101
- Appendix 4E & Annual Report
Later from Island Pharmaceuticals
- Island receives R&D tax refund for FY2023
- Screening commences for ISLA-101 Single Ascending Dose Study
- Island doses first cohort in ISLA-101 clinical trial
- Second cohort dosed in ISLA-101 Single Ascending Dose study
- R&D Tax Incentive loan facility secured with Radium Capital
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals